Cigna’s Pharmacy Revenue Rose 9% While Profit Fell 22%. Can $3 Billion Fix the Margin?

Cigna’s largest pharmacy business is processing more revenue but producing less profit. The investment question is whether that is a temporary cost of renewing clients and rebuilding the platform—or evidence that scale is becoming less valuable.

In the third quarter of 2026, The Cigna Group reported $73.7 billion of total revenue, up 6%. Adjusted income from operations was almost unchanged at $2.10 billion. The gap between those two growth rates becomes clearer inside Evernorth, the health-services division that contains Cigna’s pharmacy-benefit operations.

Evernorth adjusted revenue rose 6% to $63.8 billion, but adjusted pretax income fell 4% to $1.83 billion. Its adjusted pretax margin declined to 2.9% from 3.2%.

For the maintained financial record, see Cigna’s stock profile. This analysis asks whether management’s new $3 billion modernization programme can turn pharmacy scale into better owner economics.

The pharmacy-benefit engine lost leverage

Within Evernorth, Pharmacy Benefit Services revenue increased 9% to $37.3 billion. Adjusted pretax income fell 22% to $765 million from $975 million.

That is a meaningful deterioration: each additional dollar of reported revenue did not carry the same profit contribution as a year earlier. The segment’s simple adjusted pretax margin, calculated from those figures, fell to about 2.1% from 2.9%.

Management attributed the decline primarily to large-client contract renewals and strategic investments. That explanation matters, but it does not make the cost temporary by itself. Competitive renewals can reset economics for years, while investments only create value if they reduce future costs, improve service or deepen relationships enough to earn an adequate return.

Cigna’s other Evernorth operation provided a useful contrast. Specialty and Care Services revenue rose only 1% to $26.5 billion, yet adjusted pretax income increased 15% to $1.06 billion. Management pointed to organic specialty growth and wider adoption of biosimilars and specialty generics.

The mix therefore cuts both ways. Pharmacy-benefit scale is growing with weaker near-term profit, while specialty and care services are producing more income from modest revenue growth. Evernorth’s overall margin will depend on whether the stronger specialty economics can persist and whether pharmacy profitability stabilises.

Healthcare showed that margin improvement is possible

Cigna Healthcare, the insurance division, reported adjusted revenue of $11.7 billion, up 9%, and adjusted pretax income of $1.19 billion, up 15%. Its adjusted pretax margin improved to 10.2% from 9.7%.

The medical-care ratio was 85.0%, slightly above 84.8% a year earlier. That ratio represents medical costs as a share of premiums. A higher figure is generally a headwind, but the change was small enough that broader revenue growth and expense management still supported profit expansion.

This matters because the consolidated business is not uniformly under pressure. Cigna Healthcare and Specialty and Care Services both grew adjusted profit faster than revenue. The problem is concentrated in the pharmacy-benefit operation, which makes the remedial plan easier to assess than a vague company-wide slowdown.

What does the $3 billion plan actually promise?

Cigna announced a multi-year programme called Accelerate to One, with a stated goal of delivering $3 billion of savings and productivity improvements. Management described modernising infrastructure, using artificial intelligence and simplifying operations. It also set long-term targets of 10% to 14% compound annual growth in adjusted earnings per share and roughly $50 billion of cumulative operating cash flow through 2030.

Those are management targets, not recorded savings or cash. The relevant test is not the headline amount. Investors need to see lower recurring costs without service disruption, restructuring charges that do not repeatedly replace one another, and segment income that grows without relying mainly on adjustments or buybacks.

Management raised its 2026 adjusted EPS outlook by $0.15 to at least $30.60. That indicates confidence in the current year, but a small guidance increase cannot establish that a multi-year programme will close the Pharmacy Benefit Services margin gap.

Cash conversion has not yet accelerated

For the first nine months, operating cash flow was $3.28 billion, down from $3.45 billion. Capital spending on property, equipment and software declined to $800 million from $900 million.

Cigna repurchased about $500 million of shares, compared with approximately $2.6 billion in the prior-year period. Less buyback spending preserves cash, but it also means per-share growth has less help from a rapidly shrinking share count.

The balance sheet provides room to execute. At 30 September, cash and short-term investments totalled $6.5 billion, the revolving credit facility had $6.5 billion of undrawn capacity, and debt represented 41.8% of total capital, down from 43.0% at year-end.

Liquidity is not the same as productivity. If the programme works, operating cash flow should eventually grow faster than revenue and require less explanation from working-capital timing or one-off actions.

What would confirm the thesis?

The clearest positive signal would be Pharmacy Benefit Services adjusted profit returning to growth while revenue remains durable. Evernorth’s margin should stabilise without weakening Specialty and Care Services. Cigna Healthcare’s margin and medical-care ratio should also remain controlled, showing that one division is not compensating for another through unsustainable pricing or cost restraint.

Cash is the second test. Operating cash flow should begin to reflect the promised productivity, and capital spending plus restructuring costs should be assessed against realised savings rather than the $3 billion target alone.

The counter-case is that contract renewals have reset pharmacy economics lower, modernization requires prolonged spending, and adjusted per-share growth depends more on exclusions and future buybacks than better operating returns.

Cigna does not have a revenue-growth problem. It has a conversion problem inside its biggest pharmacy operation. The $3 billion programme becomes credible when that revenue starts producing more segment income and cash—not when the savings target is announced.

Explore Compound’s earnings hub and our guide to investment diversification.

Reported figures are in US dollars and relate to Q3 or the first nine months of 2026 as stated. Adjusted income and segment margins are non-GAAP measures. Facts come from Cigna’s 5 November results release and Form 10-Q; calculations and interpretation are Compound’s. Management targets and explanations are identified as such. General information, not personal investment advice.

Cover: Alexander Grey, Unsplash, under the Unsplash License. Archival photograph published 4 July 2019; cropped for publication and not presented as a Cigna facility or current event.